Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's ' Traumatic Brain Injury Pipeline Insight 2025 ' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Traumatic Brain Injury Treatment Landscape. Click here to read more @ Traumatic Brain Injury Pipeline Outlook
Key Takeaways from the Traumatic Brain Injury Pipeline Report
In June 2025, Hope Biosciences announced a study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury.
In June 2025, Merz Pharmaceuticals GmbH conducted a study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.
In June 2025, Ipsen organized a study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
DelveInsight's Traumatic Brain Injury pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Traumatic Brain Injury treatment.
The leading Traumatic Brain Injury Companies such as Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others.
Promising Traumatic Brain Injury Pipeline Therapies such as Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, Rivastigmine, VAS203, Dexanabinol and others.
Discover groundbreaking developments in Traumatic Brain Injury Therapies! Gain in-depth knowledge of key Traumatic Brain Injury Emerging Drugs, and market opportunities @ Traumatic Brain Injury Clinical Trials Assessment
Traumatic Brain Injury Emerging Drugs Profile
ONP-002: Oragenics, Inc.
ONP-002 is a First-in-Class Enantiomeric-Neurosteroid being developed for the treatment of mild Traumatic Brain Injury (mTBI) aka concussion. ONP-002 diffuses intracellularly to induce steroid receptors found in neurons, glia, and the endothelium of the blood brain-barrier. The induction of the ONP-002 receptors activates multiple gene response elements leading to the production of mRNA transcripts and subsequently proteins that reduce inflammation, oxidative stress, and swelling. In addition, ONP-002 induces macro-autophagy to reduce the build-up of extra- and intra-cellular debris that can cause chronic neurological diseases associated with dementia. Currently, the drug is in the Phase II stage of its development for the treatment of Traumatic Brain Injury.
MR-301: SHINKEI Therapeutics, Inc
MR-301 – Amantadine HCl Intravenous (IV) Solution is SHINKEI's most advanced program. Amantadine HCl is one of the most commonly prescribed off-label medications for patients with prolonged disorders of consciousness after TBI. Amantadine HCl increases dopamine availability in the synapse by inhibiting the activation of dopaminergic receptors. Amantadine HCl has been approved as a prescription oral product in the U.S since 1966 and, as such, has a long history of safe use in the U.S. and globally. Preliminary studies in preclinical models and patients with TBI have suggested that amantadine may promote functional recovery with high levels of safety. Currently, the drug is in Phase II stage of its development for the treatment of Traumatic Brain Injury.
ACD 856: AlzeCure
ACD 856 is a small molecule, positive allosteric modulator of Trk receptors, which mediate the effects of BDNF, NGF, and other neurotrophic factors. ACD856 increases the kinase activity of Trk receptors and enhances the effects of BDNF or NGF on survival, neuronal function, and synaptic plasticity. This is intended to make up for loss of BDNF and NGF signaling that occurs in AD. This compound is taken orally. The compound improves mitochondrial function and increases BDNF expression in cells, and shows antidepressant activity in mice. Currently, the drug is in Phase I stage of its development for the treatment of Traumatic Brain Injury.
AP-188: Algernon Pharmaceutical
AP-188 (N,N-Dimethyltryptamine, or DMT) is a potential treatment for stroke and traumatic brain injury (TBI) recovery. DMT is a naturally occurring compound that is part of the tryptamine family, which also includes psilocybin and psilocin. DMT is naturally occurring and found in plants and animals and is expressed naturally in humans in times of great physiological stress, including cardiac arrest and childbirth. It is assumed to have roles in cell protection, regeneration, and immunity as well. The drug is a sigma receptor agonist, and some evidence points to sigma receptor binding as a critical factor in the drug's protective actions. Psychedelic drugs as a class have also demonstrated an ability to promote neuritogenesis both in vivo and in vitro. The effects are believed to be through agonism of the 5-HT2A receptor, although other receptors, including sigma, may be involved. DMT increases expression of Brain Derived Neurotropic Factor (BDNF), which promotes neuroplasticity: a key factor in the brain's ability to form and reorganize synaptic connections, which are needed for healing following a brain injury. DMT is also known to bind to a number of other receptors, including various 5-HT, dopamine, adrenergic, and trace amine receptors. Currently, the drug is in Phase I stage of its development for the treatment of Traumatic Brain Injury.
The Traumatic Brain Injury Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Traumatic Brain Injury with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Traumatic Brain Injury Treatment.
Traumatic Brain Injury Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Traumatic Brain Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Traumatic Brain Injury market
Stay informed about the Traumatic Brain Injury pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Traumatic Brain Injury Unmet Needs
Traumatic Brain Injury Companies
Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others.
Traumatic Brain Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Traumatic Brain Injury Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Transform your understanding of the Traumatic Brain Injury Pipeline! See the latest progress in drug development and clinical research @ Traumatic Brain Injury Market Drivers and Barriers, and Future Perspectives
Scope of the Traumatic Brain Injury Pipeline Report
Coverage- Global
Traumatic Brain Injury Companies- Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others.
Traumatic Brain Injury Pipeline Therapies- Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, Rivastigmine, VAS203, Dexanabinol and others.
Traumatic Brain Injury Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Traumatic Brain Injury Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Research-Access the Full Traumatic Brain Injury Pipeline Analysis Today! @ Traumatic Brain Injury Drugs and Companies
Table of Contents
Introduction
Executive Summary
Traumatic Brain Injury: Overview
Pipeline Therapeutics
Therapeutic Assessment
Traumatic Brain Injury– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ONP-002: Oragenics, Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ACD 856: AlzeCure
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Traumatic Brain Injury Key Companies
Traumatic Brain Injury Key Products
Traumatic Brain Injury- Unmet Needs
Traumatic Brain Injury- Market Drivers and Barriers
Traumatic Brain Injury- Future Perspectives and Conclusion
Traumatic Brain Injury Analyst Views
Traumatic Brain Injury Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/traumatic-brain-injury-tbi-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
5 hours ago
- CTV News
Over 14 million people could die from U.S. foreign aid cuts: study
Demonstrators and lawmakers rally against U.S. President Donald Trump and his ally Elon Musk as they disrupt the federal government, including dismantling the U.S. Agency for International Development, which administers foreign aid approved by Congress, on Capitol Hill in Washington, Wednesday, Feb. 5, 2025. (AP Photo/J. Scott Applewhite) PARIS, France — More than 14 million of the world's most vulnerable people, a third of them small children, could die because of the Trump administration's dismantling of U.S. foreign aid, research projected on Tuesday. The study in the prestigious Lancet journal was published as world and business leaders gather for a UN conference in Spain this week hoping to bolster the reeling aid sector. The U.S. Agency for International Development (USAID) had provided over 40 percent of global humanitarian funding until Donald Trump returned to the White House in January. Two weeks later, Trump's then-close advisor -- and world's richest man -- Elon Musk boasted of having put the agency 'through the woodchipper'. The funding cuts 'risk abruptly halting -- and even reversing -- two decades of progress in health among vulnerable populations,' warned study co-author Davide Rasella, a researcher at the Barcelona Institute for Global Health (ISGlobal). 'For many low- and middle-income countries, the resulting shock would be comparable in scale to a global pandemic or a major armed conflict,' he said in a statement. Looking back over data from 133 nations, the international team of researchers estimated that USAID funding had prevented 91 million deaths in developing countries between 2001 and 2021. They also used modelling to project how funding being slashed by 83 percent -- the figure announced by the U.S. government earlier this year -- could affect death rates. The cuts could lead to more than 14 million avoidable deaths by 2030, the projections found. That number included over 4.5 million children under the age of five -- or around 700,000 child deaths a year. For comparison, around 10 million soldiers are estimated to have been killed during World War I. Programmes supported by USAID were linked to a 15-percent decrease in deaths from all causes, the researchers found. For children under five, the drop in deaths was twice as steep at 32 percent. USAID funding was found to be particularly effective at staving off preventable deaths from disease. There were 65 percent fewer deaths from HIV/AIDS in countries receiving a high level of support compared to those with little or no USAID funding, the study found. Deaths from malaria and neglected tropical diseases were similarly cut in half. 'Time to scale up' After USAID was gutted, several other major donors including Germany, the UK and France followed suit in announcing plans to slash their foreign aid budgets. These aid reductions, particularly in the European Union, could lead to 'even more additional deaths in the coming years,' study co-author Caterina Monti of ISGlobal said. But the grim projections for deaths were based on the current amount of pledged aid, so could rapidly come down if the situation changes, the researchers emphasised. Dozens of world leaders are meeting in the Spanish city of Seville this week for the biggest aid conference in a decade. The U.S., however, will not attend. 'Now is the time to scale up, not scale back,' Rasella said. Before its funding was slashed, USAID represented 0.3 percent of all U.S. federal spending. 'U.S. citizens contribute about 17 cents per day to USAID, around $64 per year,' said study co-author James Macinko of the University of California, Los Angeles. 'I think most people would support continued USAID funding if they knew just how effective such a small contribution can be to saving millions of lives.'
CTV News
7 hours ago
- CTV News
The cost of loneliness can be death. Here's how to find good friends
After working from home all day, your takeout order arrives and you start binge-watching your favorite show alone. Sounds ideal, right? Except doing this routinely could shorten your life. And that's not because of the nutritional content of your dinner. It's because having strong, positive relationships is one of the best ways to extend your life, according to research. 'Human beings just are a fundamentally social species. We have a fundamental need to belong,' said Dr. Amit Kumar, associate professor of marketing and psychology at the University of Texas at Austin's McCombs School of Business. With everything else you have going on, why should you make a change? Because the cost of loneliness is huge. 'The mortality impact of being socially disconnected is similar to that caused by smoking up to 15 cigarettes a day, and even greater than that associated with obesity and physical inactivity,' wrote then US Surgeon General Dr. Vivek H. Murthy in his 2023 advisory on the 'healing effects' of social connection . The lack of strong social ties has been linked to a greater risk of problems with health or well-being, including more stress, high blood pressure, premature death and poor coping skills. But finding friends as an adult can be hard. Some people's mindsets hinder their ability to make connections, while a lack of affordable places to meet is a challenge for others, said Danielle Bayard Jackson, director of the Women's Relational Health Institute. But the effort is worth it. Here's how Jackson and other experts suggest you combat those limitations and find your community. Breaking down barriers to friendship If you want to make more connections in your life, consider how you might be counteracting that goal and prepare to change, said Jackson, author of 'Fighting for Our Friendships: The Science and Art of Conflict and Connection in Women's Relationships.' Many people have a fear of rejection, real or perceived, while others have social anxiety, Jackson said. But if you never take risks, Kumar noted, you never give your brain a chance to see that you actually can socialize. Practicing cognitive behavioral therapy or setting yourself up for 'micro' moments to put yourself out there can help you regulate social anxiety and rejection-sensitivity, experts said. Not everyone is going to like you, and you need to learn to regulate your emotional response to that. That could look like noting the sting and thinking, 'Well, that was awkward' — but not immediately labeling that person a jerk or deciding something about you is defective. 'Some psychologists call it exposure therapy,' Jackson said. 'I've seen them assign a client the task of going and asking for crazy things and intentionally trying to go and collect nos.' Engage with a waiter a bit longer than normal and ask for a menu accommodation you know they will decline, Jackson said. Check out at the grocery store with a cashier instead of self-checkout to practice your social skills. If time is an issue, think about canceling some commitments so you can prioritize your social life, experts said. But you should also change what you consider acceptable hangouts — setting time limits is OK, especially when the alternative is not seeing anyone at all. Dr. Lauren Cook, a clinical psychologist, suggests doing mundane activities with friends more often instead of always having bigger, less frequent events focused on catching up. If you want to see someone but also need to run errands, hit the gym or fold laundry, ask them to join you. Instead of drinks on a Friday, plan a short Tuesday game night and ask your guests to eat dinner beforehand so you only have to provide a snack. Defy environmental challenges to socializing Some people cite the 'collapse of third places' as a hindrance to making friends, Jackson said. That's true, she added, but those places are closing in part because of low attendance. Today's culture of convenience is also to blame, Jackson and Cook said — think grocery delivery orders, mobile order counters, digital reading devices or livestreamed religious services. These have many perks, especially for people with mobility issues, 'but I cannot help but to think about the cost,' Jackson said. 'We tend to romanticize those serendipitous moments of, like, you're in a coffee shop and you start chatting with the girl in front of you and you guys hit it off,' Jackson said. But that can't happen if we're acting like 'little night cooters,' Cook said — quickly hopping out, getting our food and then going back to our caves. When clients seek Jackson's help with finding friends, they list all their delivery subscriptions and other conveniences — such as frequent mobile orders — and then eliminate some, which lead to those serendipitous moments. Don't think in black or white, Jackson said. 'If you see it as zero friends or go out and make besties, that's a lot,' she added. But if you see all that's available to you — like the neighbor or moviegoer you always run into — you can see what happens. Finally, get off your phone. When you're always zoned in on your screen, you appear standoffish and won't notice people you might like. Go out to meet likeminded people To determine where to meet people, consider your values and your ideal friend, Jackson said. If you love helping people, look for volunteering opportunities. If your ideal friend reads books, where would she be on a Wednesday night? Probably at a book club meeting or a bookstore, so go to one. Frequent local libraries, farmers markets and parks. Look online for interest clubs or events, or try an app for finding friends nearby. Take a class on something you have always wanted to do, such as learning a specific dance style or cooking a special cuisine. Maybe even reach out to an old friend you have lost touch with, said psychologist Dr. Marisa G. Franco, an associate fellow at the University of Maryland honors program and author of 'Platonic: How the Science of Attachment Can Help You Make — and Keep — Friends.' We often underestimate how happy people will be to hear from us, she noted. When Cook became a new mom, she brought her baby along on her walks and made many friends by asking other women about their babies and talking about her own. Cook also suggested wearing something that could be a conversation starter, such as a T-shirt featuring your favorite artist. And don't forget you can be a leader, Cook said. 'A lot of people are hoping these opportunities will just fall in their lap. If you're not finding it, build it.' Cook recalled when her friends hosted dinners they called 'friends of friends.' They would invite a friend who also had to bring someone. 'That completely built out their whole social world because their friends were all getting to know each other,' Cook said. 'It became this popular thing where there was a wait list.' Another person couldn't find a quilting club for millennials, so they started a monthly class in a rented space, Cook said. That do-it-yourself spirit is what sparked some of the platforms that matchmake strangers for restaurant dinners or provide spaces for people to start something themselves. Those initiatives include The Lonely Girls Club in the United Kingdom; California's Groundfloor, an 'after-school club' for millennials; RealRoots in the United States; and the global-based Time Left. How to talk to strangers Small talk may seem annoying, but it's necessary, said Cook, who also wrote 'Generation Anxiety: A Millennial and Gen Z Guide to Staying Afloat in an Uncertain World.' Deep relationships take time to build. If you find yourself running out of topics, Cook recommends asking questions about their favorite things that are relevant to the situation — if you're at a jazz bar, for example, ask someone about their favorite jazz artists. If your platonic interest loves hiking, say you'll send them links to a couple of good spots if they give you their number or Instagram, Jackson suggested. Later that night, send them the links. After a week, ask if they went and keep talking. Cook also suggests using the 'listen and link' technique. As you're listening to someone, think about what you can link to the conversation, use that and build from there. If someone's talking about their trip to Costa Rica and you love monkeys, ask what kinds of monkeys they saw in Costa Rica. One of my favorite ways to keep a conversation going with someone new? Staying curious. When someone is totally new to you, there is a whole decades-long world of information to learn about them. When you're aware of that, how could you ever have nothing to talk about? Cook agrees. How to keep a friend Although many people know romantic partnerships require consistent effort and nurturing, many think friendship should be the opposite: easy, natural and organic, Jackson said. This idea may be because growing up, we made friends more easily because we had classes or sports practice with them every day. But in adulthood, that idea is a falsehood that leads to fizzled-out friendships and loneliness, Jackson said. Maintaining friendships takes a lot of intention, experts said. Set reminders to check in, be a good listener, don't be judgmental and remember what your new acquaintances like so you can suggest meaningful ways to spend time together — and maybe even live longer. By Kristen Rogers.
Globe and Mail
8 hours ago
- Globe and Mail
Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's ' Traumatic Brain Injury Pipeline Insight 2025 ' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Traumatic Brain Injury Treatment Landscape. Click here to read more @ Traumatic Brain Injury Pipeline Outlook Key Takeaways from the Traumatic Brain Injury Pipeline Report In June 2025, Hope Biosciences announced a study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury. In June 2025, Merz Pharmaceuticals GmbH conducted a study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation. In June 2025, Ipsen organized a study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity. DelveInsight's Traumatic Brain Injury pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Traumatic Brain Injury treatment. The leading Traumatic Brain Injury Companies such as Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others. Promising Traumatic Brain Injury Pipeline Therapies such as Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, Rivastigmine, VAS203, Dexanabinol and others. Discover groundbreaking developments in Traumatic Brain Injury Therapies! Gain in-depth knowledge of key Traumatic Brain Injury Emerging Drugs, and market opportunities @ Traumatic Brain Injury Clinical Trials Assessment Traumatic Brain Injury Emerging Drugs Profile ONP-002: Oragenics, Inc. ONP-002 is a First-in-Class Enantiomeric-Neurosteroid being developed for the treatment of mild Traumatic Brain Injury (mTBI) aka concussion. ONP-002 diffuses intracellularly to induce steroid receptors found in neurons, glia, and the endothelium of the blood brain-barrier. The induction of the ONP-002 receptors activates multiple gene response elements leading to the production of mRNA transcripts and subsequently proteins that reduce inflammation, oxidative stress, and swelling. In addition, ONP-002 induces macro-autophagy to reduce the build-up of extra- and intra-cellular debris that can cause chronic neurological diseases associated with dementia. Currently, the drug is in the Phase II stage of its development for the treatment of Traumatic Brain Injury. MR-301: SHINKEI Therapeutics, Inc MR-301 – Amantadine HCl Intravenous (IV) Solution is SHINKEI's most advanced program. Amantadine HCl is one of the most commonly prescribed off-label medications for patients with prolonged disorders of consciousness after TBI. Amantadine HCl increases dopamine availability in the synapse by inhibiting the activation of dopaminergic receptors. Amantadine HCl has been approved as a prescription oral product in the U.S since 1966 and, as such, has a long history of safe use in the U.S. and globally. Preliminary studies in preclinical models and patients with TBI have suggested that amantadine may promote functional recovery with high levels of safety. Currently, the drug is in Phase II stage of its development for the treatment of Traumatic Brain Injury. ACD 856: AlzeCure ACD 856 is a small molecule, positive allosteric modulator of Trk receptors, which mediate the effects of BDNF, NGF, and other neurotrophic factors. ACD856 increases the kinase activity of Trk receptors and enhances the effects of BDNF or NGF on survival, neuronal function, and synaptic plasticity. This is intended to make up for loss of BDNF and NGF signaling that occurs in AD. This compound is taken orally. The compound improves mitochondrial function and increases BDNF expression in cells, and shows antidepressant activity in mice. Currently, the drug is in Phase I stage of its development for the treatment of Traumatic Brain Injury. AP-188: Algernon Pharmaceutical AP-188 (N,N-Dimethyltryptamine, or DMT) is a potential treatment for stroke and traumatic brain injury (TBI) recovery. DMT is a naturally occurring compound that is part of the tryptamine family, which also includes psilocybin and psilocin. DMT is naturally occurring and found in plants and animals and is expressed naturally in humans in times of great physiological stress, including cardiac arrest and childbirth. It is assumed to have roles in cell protection, regeneration, and immunity as well. The drug is a sigma receptor agonist, and some evidence points to sigma receptor binding as a critical factor in the drug's protective actions. Psychedelic drugs as a class have also demonstrated an ability to promote neuritogenesis both in vivo and in vitro. The effects are believed to be through agonism of the 5-HT2A receptor, although other receptors, including sigma, may be involved. DMT increases expression of Brain Derived Neurotropic Factor (BDNF), which promotes neuroplasticity: a key factor in the brain's ability to form and reorganize synaptic connections, which are needed for healing following a brain injury. DMT is also known to bind to a number of other receptors, including various 5-HT, dopamine, adrenergic, and trace amine receptors. Currently, the drug is in Phase I stage of its development for the treatment of Traumatic Brain Injury. The Traumatic Brain Injury Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Traumatic Brain Injury with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Traumatic Brain Injury Treatment. Traumatic Brain Injury Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Traumatic Brain Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Traumatic Brain Injury market Stay informed about the Traumatic Brain Injury pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Traumatic Brain Injury Unmet Needs Traumatic Brain Injury Companies Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others. Traumatic Brain Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Traumatic Brain Injury Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Traumatic Brain Injury Pipeline! See the latest progress in drug development and clinical research @ Traumatic Brain Injury Market Drivers and Barriers, and Future Perspectives Scope of the Traumatic Brain Injury Pipeline Report Coverage- Global Traumatic Brain Injury Companies- Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others. Traumatic Brain Injury Pipeline Therapies- Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, Rivastigmine, VAS203, Dexanabinol and others. Traumatic Brain Injury Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Traumatic Brain Injury Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Research-Access the Full Traumatic Brain Injury Pipeline Analysis Today! @ Traumatic Brain Injury Drugs and Companies Table of Contents Introduction Executive Summary Traumatic Brain Injury: Overview Pipeline Therapeutics Therapeutic Assessment Traumatic Brain Injury– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) ONP-002: Oragenics, Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) ACD 856: AlzeCure Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Traumatic Brain Injury Key Companies Traumatic Brain Injury Key Products Traumatic Brain Injury- Unmet Needs Traumatic Brain Injury- Market Drivers and Barriers Traumatic Brain Injury- Future Perspectives and Conclusion Traumatic Brain Injury Analyst Views Traumatic Brain Injury Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
